| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -9.9 | -16.4 |
| EPS (diluted, $ a share) | $-0.20 | $-0.36 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: HOWL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Werewolf Therapeutics, Inc.: key numbers
- Share price
- $0.9908Close, Nov 16
- Market cap
- $48.2M
- Shares outstanding
- 48.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Werewolf Therapeutics, Inc.
All →Werewolf Therapeutics Clinical Trial Data
Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.